摘要
目的探讨螺内酯对扩张型心肌病心力衰竭的治疗作用。方法将119例患者按入选顺序随机分编入治疗组和对照组。对照组接受常规治疗(β受体阻滞剂+ACEI+地高辛+速尿),治疗组在对照组的基础上加安体舒通(螺内酯()20mg BID)。结果治疗1a后,左房、左室内经明显小于对照组,左室射血分数,左室短轴缩短率明显高于对照组。结论螺内酯对扩张型心肌病心力衰竭有效,可改善心功能和改善心室重构,改善预后。
[Objective] To evaluate the clinical therapeutic efficacy and safety of spironolactone in patient with heart failure of dilated cardiomyopathy. [Methods] 119 patients with heart failure of dilated cardiomyopathy were divided into the treatment group （60 cases） and the control group （59 cases） randomly. Routine general therapy （β- blocker＋ACEI＋ Digoxin＋ Furosemide） was given to the control group, the treatment group took spironolactone 40mg per day besides routine general therapy. The echocardiography was performed before and after 1 year of the treatment. [Results] 1 year after treatment, LAD, LVEDD, LVESD diminished significantly in both group; but diminished more significantly in treatment group than in control group （P 〈0.05）. LVEF, FS improved significantly in both group; but improved more significantly in treatment group than in control group （P 〈0.05）. [Conclusion] Spironolactone is absolutely reliable in the treatment of heart failure of dilated cardiomyopathy.
出处
《中国医学工程》
2006年第4期428-429,432,共3页
China Medical Engineering
